vs
Cardio Diagnostics Holdings, Inc.（CDIO）与Enveric Biosciences, Inc.（ENVB）财务数据对比。点击上方公司名可切换其他公司
Enveric Biosciences, Inc.同比增速更快（-11.1% vs -21.2%）
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
Enveric Biosciences是一家临床阶段生物技术企业，专注于开发大麻素及相关分子衍生的新型疗法，管线覆盖心理健康障碍、癌症治疗相关不良反应等未被满足的医疗需求，主要在北美及欧洲生物医药市场开展业务。
CDIO vs ENVB — 直观对比
营收规模更大
CDIO
是对方的-14.2倍
$-250
营收增速更快
ENVB
高出10.1%
-21.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6K | $-250 |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | — | 877569.2% |
| 净利率 | — | — |
| 营收同比 | -21.2% | -11.1% |
| 净利润同比 | 3.6% | — |
| 每股收益（稀释后） | — | $-23.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDIOENVB
| Q4 25 | $3.6K | $-250 | ||
| Q3 25 | $2.9K | — | ||
| Q2 25 | $7.5K | $-132 | ||
| Q4 24 | $4.5K | $-225 | ||
| Q3 24 | $6.6K | $-217 | ||
| Q2 24 | $7.9K | $-35 | ||
| Q1 24 | $15.9K | — | ||
| Q4 23 | — | $566 |
净利润CDIOENVB
| Q4 25 | — | — | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-1.7M | $-2.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.4M | $-2.1M | ||
| Q2 24 | $-1.3M | $-1.9M | ||
| Q1 24 | $-4.2M | — | ||
| Q4 23 | — | — |
营业利润率CDIOENVB
| Q4 25 | — | 877569.2% | ||
| Q3 25 | -59950.9% | — | ||
| Q2 25 | -22457.5% | 1908370.5% | ||
| Q4 24 | — | 1410589.3% | ||
| Q3 24 | -21412.9% | 959996.3% | ||
| Q2 24 | -16295.6% | 5422660.0% | ||
| Q1 24 | -26105.3% | — | ||
| Q4 23 | — | -421265.0% |
净利率CDIOENVB
| Q4 25 | — | — | ||
| Q3 25 | -60053.8% | — | ||
| Q2 25 | -22517.7% | 1908470.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -21467.6% | 960383.4% | ||
| Q2 24 | -16365.9% | 5369697.1% | ||
| Q1 24 | -26140.0% | — | ||
| Q4 23 | — | — |
每股收益（稀释后）CDIOENVB
| Q4 25 | — | $-23.24 | ||
| Q3 25 | $-0.98 | — | ||
| Q2 25 | $-0.97 | $-0.97 | ||
| Q4 24 | — | $-172.45 | ||
| Q3 24 | $-1.73 | $-43.10 | ||
| Q2 24 | $-1.71 | $-3.72 | ||
| Q1 24 | $-5.93 | — | ||
| Q4 23 | — | $-114.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.0M | $4.2M |
| 总资产 | $7.8M | $5.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
股东权益CDIOENVB
| Q4 25 | $7.0M | $4.2M | ||
| Q3 25 | $8.2M | — | ||
| Q2 25 | $9.7M | $2.2M | ||
| Q4 24 | $9.6M | $1.6M | ||
| Q3 24 | $3.7M | $4.0M | ||
| Q2 24 | $3.1M | $5.4M | ||
| Q1 24 | $3.0M | — | ||
| Q4 23 | — | $2.0M |
总资产CDIOENVB
| Q4 25 | $7.8M | $5.1M | ||
| Q3 25 | $8.8M | — | ||
| Q2 25 | $10.4M | $3.5M | ||
| Q4 24 | $10.6M | $3.1M | ||
| Q3 24 | $4.5M | $4.8M | ||
| Q2 24 | $4.0M | $6.1M | ||
| Q1 24 | $4.3M | — | ||
| Q4 23 | — | $4.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $-1.8M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | — |
| 自由现金流率自由现金流/营收 | -166361.5% | — |
| 资本支出强度资本支出/营收 | 5269.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-14.3M | — |
8季度趋势，按日历期对齐
经营现金流CDIOENVB
| Q4 25 | $-5.7M | $-1.8M | ||
| Q3 25 | $-1.4M | — | ||
| Q2 25 | $-1.6M | $-1.9M | ||
| Q4 24 | $-5.0M | $-1.3M | ||
| Q3 24 | $-1.2M | $-927.1K | ||
| Q2 24 | $-1.2M | $-2.9M | ||
| Q1 24 | $-1.2M | — | ||
| Q4 23 | — | $-1.8M |
自由现金流CDIOENVB
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-1.6M | — | ||
| Q4 24 | $-5.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-1.3M | — | ||
| Q4 23 | — | $-1.8M |
自由现金流率CDIOENVB
| Q4 25 | -166361.5% | — | ||
| Q3 25 | -54509.7% | — | ||
| Q2 25 | -21273.1% | — | ||
| Q4 24 | -115422.6% | — | ||
| Q3 24 | -17942.3% | — | ||
| Q2 24 | -17513.3% | — | ||
| Q1 24 | -7866.9% | — | ||
| Q4 23 | — | -309375.1% |
资本支出强度CDIOENVB
| Q4 25 | 5269.1% | — | ||
| Q3 25 | 5703.5% | — | ||
| Q2 25 | 250.1% | — | ||
| Q4 24 | 4759.9% | — | ||
| Q3 24 | 353.3% | — | ||
| Q2 24 | 2133.4% | — | ||
| Q1 24 | 125.5% | — | ||
| Q4 23 | — | 2.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
